The study, which is set to begin in the third quarter of 2025, will be a randomized, double-blind, placebo-controlled trial involving 40 stroke patients in Europe.

Dr. Nardai, a leading cerebrovascular disease specialist, is currently the Head of the Department of Neurointervention at Semmelweis University in Budapest, Hungary. He previously led a preclinical study published in Experimental Neurology in May 2020, which demonstrated that rats treated with sub-hallucinogenic doses of DMT showed near-complete motor function recovery and smaller infarct volumes compared to untreated control groups. This research provided the basis for Algernon’s clinical investigation into DMT as a potential neuroprotective agent for stroke recovery.

“The primary endpoint of the planned Phase 2a study will be safety,” said Dr. Nardai in the news release. “However, stroke clinicians worldwide will also be watching for positive signals regarding lesion volume, biomarkers, motor function, cognitive function, depression, and mortality.””

Algernon Pharmaceuticals Inc. (AGN: CSE; AGNPF: OTCQB; AGW0:XFRA) subsidiary Algernon NeuroScience has appointed Dr. Sandor Nardai as Principal Investigator for its upcoming Phase 2a DMT stroke study. Find out how this trial could reshape stroke recovery research.